Prostate Specific Antigen Recurrence After Definitive Therapy

Journal of Urology

Volumn 177, Issue 6, 2007, Pages 1985-1991

  Freedland, Stephen J ^a,b   Moul, Judd W ^b  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

castration; prostate; prostate specific antigen; prostatic neoplasms; salvage therapy

Indexed keywords

BICALUTAMIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; BREAST AUGMENTATION; BREAST TENDERNESS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; CRYOTHERAPY; HISTORY; HUMAN; LITERATURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SALVAGE THERAPY; SIDE EFFECT; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; SALVAGE THERAPY;

EID: 34248222598     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.01.137     Document Type: Review

References (50)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106
2. Greene K.L., Cowan J.E., Cooperberg M.R., Meng M.V., DuChane J., and Carroll P.R. Who is the average patient presenting with prostate cancer?. Urology 66 (2005) 76
3. Han M., Partin A.W., Pound C.R., Epstein J.I., and Walsh P.C. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28 (2001) 555
4. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591
5. D'Amico A.V., Moul J.W., Carroll P.R., Sun L., Lubeck D., and Chen M.H. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95 (2003) 1376
6. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., Dorey F.J., Walsh P.C., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433
7. Ward J.F., Blute M.L., Slezak J., Bergstralh E.J., and Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 170 (2003) 1872
8. Amling C.L., Bergstralh E.J., Blute M.L., Slezak J.M., and Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?. J Urol 165 (2001) 1146
9. Freedland S.J., Sutter M.E., Dorey F., and Aronson W.J. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Urology 61 (2003) 365
10. Horwitz E.M., Vicini F.A., Ziaja E.L., Dmuchowski C.F., Stromberg J.S., Martinez A.A., and American Society of Therapeutic Radiology and Oncology. The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. Int J Radiat Oncol Biol Phys 41 (1998) 267
11. Horwitz E.M., Thames H.D., Kuban D.A., Levy L.B., Kupelian P.A., Martinez A.A., et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol 173 (2005) 797
12. Carter H.B., Pearson J.D., Metter E.J., Brant L.J., Chan D.W., Andres R., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215
13. Zagars G.K., and Pollack A. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer. Cancer 72 (1993) 832
14. Trapasso J.G., deKernion J.B., Smith R.B., and Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152 (1994) 1821
15. Okotie O.T., Aronson W.J., Wieder J.A., Liao Y., Dorey F., deKernion J.B., et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 171 (2004) 2260
16. D'Amico A.V., Cote K., Loffredo M., Renshaw A.A., and Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20 (2002) 4567
17. Patel A., Dorey F., Franklin J., and deKernion J.B. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158 (1997) 1441
18. Zagars G.K., and Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 44 (1997) 213
19. Soergel T.M., Koch M.O., Foster R.S., Bihrle R., Wahle G., Gardner T., et al. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy. J Urol 166 (2001) 2198
20. Zhou P., Chen M.H., McLeod D., Carroll P.R., Moul J.W., and D'Amico A.V. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 23 (2005) 6992
21. Pinover W.H., Horwitz E.M., Hanlon A.L., Uzzo R.G., and Hanks G.E. Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. Cancer 97 (2003) 1127
22. Slovin S.F., Wilton A.S., Heller G., and Scher H.I. Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin Cancer Res 11 (2005) 8669
23. Leventis A.K., Shariat S.F., Kattan M.W., Butler E.B., Wheeler T.M., and Slawin K.M. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 19 (2001) 1030
24. Koppie T.M., Grossfeld G.D., Nudell D.M., Weinberg V.K., and Carroll P.R. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy?. J Urol 166 (2001) 111
25. Katz M.S., Zelefsky M.J., Venkatraman E.S., Fuks Z., Hummer A., and Leibel S.A. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 21 (2003) 483
26. Stephenson A.J., Shariat S.F., Zelefsky M.J., Kattan M.W., Butler E.B., Teh B.S., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 (2004) 1325
27. Anscher M.S., Clough R., and Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. Int J Radiat Oncol Biol Phys 48 (2000) 369
28. Cox J.D., Gallagher M.J., Hammond E.H., Kaplan R.S., Schellhammer P.F., and American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. J Clin Oncol 17 (1999) 1155
29. Pazona J.F., Han M., Hawkins S.A., Roehl K.A., and Catalona W.J. Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates. J Urol 174 (2005) 1282
30. Ward J.F., Sebo T.J., Blute M.L., and Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol 173 (2005) 1156
31. Bianco Jr. F.J., Scardino P.T., Stephenson A.J., DiBlasio C.J., Fearn P.A., and Eastham J.A. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 62 (2005) 448
32. Stephenson A.J., Scardino P.T., Bianco Jr. F.J., DiBlasio C.J., Fearn P.A., and Eastham J. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol 172 (2004) 2239
33. Han K.R., Cohen J.K., Miller R.J., Pantuck A.J., Freitas D.G., Cuevas C.A., et al. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol 170 (2003) 1126
34. Anastasiadis A.G., Sachdev R., Salomon L., Ghafar M.A., Stisser B.C., Shabsigh R., et al. Comparison of health-related quality of life and prostate-associated symptoms after primary and salvage cryotherapy for prostate cancer. J Cancer Res Clin Oncol 129 (2003) 676
35. Touma N.J., Izawa J.I., and Chin J.L. Current status of local salvage therapies following radiation failure for prostate cancer. J Urol 173 (2005) 373
36. Huggins C., and Hodges C.V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 168 (2002) 9
37. Sharifi N., Gulley J.L., and Dahut W.L. Androgen deprivation therapy for prostate cancer. JAMA 294 (2005) 238
38. Bayoumi A.M., Brown A.D., and Garber A.M. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 92 (2000) 1731
39. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355 (2000) 1491
40. Klotz L., and Schellhammer P. Combined androgen blockade: the case for bicalutamide. Clin Prostate Cancer 3 (2005) 215
41. Byar D.P., and Corle D.K. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 7 (1988) 165
42. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 79 (1997) 235
43. Kirk D. Immediate vs deferred hormone treatment for prostate cancer: how safe is androgen deprivation?. BJU Int 86 suppl (2000) 220
44. Messing E.M., Manola J., Yao J., Kiernan M., Crawford D., Wilding G., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7 (2006) 472
45. Moul J.W., Wu H., Sun L., McLeod D.G., Amling C., Donahue T., et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171 (2004) 1141
46. Shipley W.U., Desilvio M., Pilepich M.V., Roach III M., Wolkov H.B., Sause W.T., et al. Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: a secondary analysis of RTOG protocol 86-10. Int J Radiat Oncol Biol Phys 64 (2006) 1162
47. Iversen P., Tyrrell C.J., Kaisary A.V., Anderson J.B., Van Poppel H., Tammela T.L., et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 164 (2000) 1579
48. McLeod D.G., Iversen P., See W.A., Morris T., Armstrong J., and Wirth M.P. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 97 (2006) 247
49. Di Lorenzo G., Perdona S., De Placido S., D'Armiento M., Gallo A., Damiano R., et al. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy. J Urol 174 (2005) 2197
50. Bhandari M.S., Crook J., and Hussain M. Should intermittent androgen deprivation be used in routine clinical practice?. J Clin Oncol 23 (2005) 8212